BioMoti Ltd today announces an agreement with a global pharmaceutical company to collaborate on the development of its lead ovarian cancer candidate, BMT101, to clinical phase 2a proof-of-concept. The collaboration agreement provides access to the partner company’s expertise including its proprietary commercial manufacturing technology and an option for the global pharmaceutical company to licence BMT101 […]